{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:19:49Z","timestamp":1787498389804,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infection is the most common cause of mortality within the first year after lung transplantation (LTx). The management of perioperative antibiotic therapy is a major issue, but little is known about worldwide practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We sent by email a survey dealing with 5 daily clinical vignettes concerning perioperative antibiotic therapy to 180 LTx centers around the world. The invitation and a weekly reminder were sent to lung transplant specialists for a single consensus answer per center during a 3-month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We received a total of 99 responses from 24 countries, mostly from Western Europe (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) and the USA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934). Systematic screening for bronchial recipient colonization before LTx was mostly performed with sputum samples (72%), regardless of the underlying lung disease. In recipients without colonization, antibiotics with activity against gram-negative bacteria resistant strains (piperacillin \/ tazobactam, cefepime, ceftazidime, carbapenems) were reported in 72% of the centers, and antibiotics with activity against methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (mainly vancomycin) were reported in 38% of the centers. For these recipients, the duration of antibiotics reported was 7\u2009days (33%) or less (26%) or stopped when cultures of donor and recipients were reported negatives (12%). In recipients with previous colonization, antibiotics were adapted to the susceptibility of the most resistant strain and given for at least 14\u2009days (67%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Practices vary widely around the world, but resistant bacterial strains are mostly targeted even if no colonization occurs. The antibiotic duration reported was longer for colonized recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-020-1151-9","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T15:03:17Z","timestamp":1588172597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Worldwide clinical practices in perioperative antibiotic therapy for lung transplantation"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-5346","authenticated-orcid":false,"given":"Benjamin","family":"Coiffard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloi","family":"Prud\u2019Homme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Hraiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Cassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Le Pavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal Alexandre","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Papazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.healun.2015.08.014","volume":"34","author":"RD Yusen","year":"2015","unstructured":"Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report--2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34:1264\u201377.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chest.2016.04.014","volume":"150","author":"SE Verleden","year":"2016","unstructured":"Verleden SE, Sacreas A, Vos R, Vanaudenaerde BM, Verleden GM. Advances in understanding bronchiolitis obliterans after lung transplantation. Chest. 2016;150:219\u201325.","journal-title":"Chest"},{"key":"1151_CR3","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","volume":"357","author":"JA Fishman","year":"2007","unstructured":"Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601\u201314.","journal-title":"N Engl J Med"},{"key":"1151_CR4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195\u2013283.","journal-title":"Am J Health Syst Pharm"},{"key":"1151_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ccm.2015.10.003","volume":"37","author":"YJ Huang","year":"2016","unstructured":"Huang YJ, LiPuma JJ. The microbiome in cystic fibrosis. Clin Chest Med. 2016;37:59\u201367.","journal-title":"Clin Chest Med"},{"key":"1151_CR6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/resp.12732","volume":"21","author":"MJ Mammen","year":"2016","unstructured":"Mammen MJ, Sethi S. COPD and the microbiome. Respirology. 2016;21:590\u20139.","journal-title":"Respirology."},{"key":"1151_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the pulmonary transplantation Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2015;34:1\u201315.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.healun.2019.01.1306","volume":"38","author":"C Lay","year":"2019","unstructured":"Lay C, Law N, Holm AM, Benden C, Aslam S. Outcomes in cystic fibrosis lung transplant recipients infected with organisms labeled as pan-resistant: an ISHLT registry\u2013based analysis. J Heart Lung Transplant. 2019;38:545\u201352.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR9","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.athoracsur.2018.08.058","volume":"107","author":"A Shah","year":"2019","unstructured":"Shah A, Pasrija C, Boulos F, et al. Decontamination and lung transplantation of a cystic fibrosis patient with resistant infections. Ann Thorac Surg. 2019;107:e239\u201341.","journal-title":"Ann Thorac Surg"},{"key":"1151_CR10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/ctr.12746","volume":"30","author":"AR Whiddon","year":"2016","unstructured":"Whiddon AR, Dawson KL, Fuentes A, Perez KK, Peterson LE, Kaleekal T. Postoperative antimicrobials after lung transplantation and the development of multidrug-resistant bacterial and Clostridium difficile infections: an analysis of 500 non-cystic fibrosis lung transplant patients. Clin Transpl. 2016;30:767\u201373.","journal-title":"Clin Transpl"},{"key":"1151_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ctr.12064","volume":"27","author":"JT Lee","year":"2013","unstructured":"Lee JT, Hertz MI, Dunitz JM, et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transpl. 2013;27:303\u201310.","journal-title":"Clin Transpl"},{"key":"1151_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1471-2334-12-375","volume":"12","author":"T Cardoso","year":"2012","unstructured":"Cardoso T, Ribeiro O, Arag\u00e3o IC, Costa-Pereira A, Sarmento AE. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis. 2012;12:375.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"1151_CR13","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1086\/320901","volume":"33","author":"R Soave","year":"2001","unstructured":"Soave R. Prophylaxis strategies for solid-organ transplantation. Clin Infect Dis. 2001;33(Suppl 1):S26\u201331.","journal-title":"Clin Infect Dis"},{"key":"1151_CR14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12890-018-0635-3","volume":"18","author":"A Tissot","year":"2018","unstructured":"Tissot A, Thomas MF, Corris PA, Brodlie M. Non tuberculous mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice. BMC Pulm Med. 2018;18:86.","journal-title":"BMC Pulm Med"},{"issue":"Suppl 7","key":"1151_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1469-0691.12641","volume":"20","author":"Y Meije","year":"2014","unstructured":"Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM, ESCMID Study Group of Infection in Compromised Hosts. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):89\u2013101.","journal-title":"Clin Microbiol Infect"},{"key":"1151_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1510\/icvts.2011.271874","volume":"13","author":"A Olland","year":"2011","unstructured":"Olland A, Falcoz PE, Kessler R, Massard G. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg. 2011;13:631\u20134.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"1151_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"1151_CR18","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1600-6143.2007.01882.x","volume":"7","author":"M Aguilar-Guisado","year":"2007","unstructured":"Aguilar-Guisado M, Givald\u00e1 J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA cohort: a multicenter prospective study. Am J Transplant. 2007;7:1989\u201396.","journal-title":"Am J Transplant"},{"key":"1151_CR19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1183\/09031936.00095214","volume":"45","author":"J Riera","year":"2015","unstructured":"Riera J, Caralt B, L\u00f3pez I, et al. Ventilator-associated respiratory infection following lung transplantation. Eur Respir J. 2015;45:726\u201337.","journal-title":"Eur Respir J"},{"key":"1151_CR20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.healun.2007.07.002","volume":"26","author":"RW Bonvillain","year":"2007","unstructured":"Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2007;26:890\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ctr.12270","volume":"28","author":"D Dudau","year":"2014","unstructured":"Dudau D, Camous J, Marchand S, et al. Incidence of nosocomial pneumonia and risk of recurrence after antimicrobial therapy in critically ill lung and heart-lung transplant patients. Clin Transpl. 2014;28:27\u201336.","journal-title":"Clin Transpl"},{"key":"1151_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.healun.2005.06.026","volume":"25","author":"PN Bonde","year":"2006","unstructured":"Bonde PN, Patel ND, Borja MC, et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant. 2006;25:99\u2013105.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12890-018-0605-9","volume":"18","author":"S Tanaka","year":"2018","unstructured":"Tanaka S, Geneve C, Tebano G, et al. Morbidity and mortality related to pneumonia and TRACHEOBRONCHITIS in ICU after lung transplantation. BMC Pulm Med. 2018;18:43.","journal-title":"BMC Pulm Med"},{"key":"1151_CR24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-6143.2005.01145.x","volume":"6","author":"I Ruiz","year":"2006","unstructured":"Ruiz I, Gavald\u00e0 J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6:178\u201382.","journal-title":"Am J Transplant"},{"key":"1151_CR25","first-page":"190","volume":"80","author":"E Bunsow","year":"2020","unstructured":"Bunsow E, Los-Arcos I, Martin-G\u00f3mez MT, et al. Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance. J Inf Secur. 2020;80:190\u20136.","journal-title":"J Inf Secur"},{"key":"1151_CR26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.healun.2013.06.021","volume":"32","author":"W Sommer","year":"2013","unstructured":"Sommer W, K\u00fchn C, Tudorache I, et al. Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm. J Heart Lung Transplant. 2013;32:1065\u201372.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/TP.0000000000000462","volume":"99","author":"JE Fildes","year":"2015","unstructured":"Fildes JE, Archer LD, Blaikley J, et al. Clinical outcome of patients transplanted with marginal donor lungs via ex vivo lung perfusion compared to standard lung transplantation. Transplantation. 2015;99:1078\u201383.","journal-title":"Transplantation"},{"key":"1151_CR28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00595-018-1730-z","volume":"49","author":"S Sugimoto","year":"2019","unstructured":"Sugimoto S, Kurosaki T, Otani S, et al. Feasibility of lung transplantation from donors mechanically ventilated for prolonged periods. Surg Today. 2019;49:254\u201360.","journal-title":"Surg Today"},{"key":"1151_CR29","first-page":"502","volume":"9","author":"M Zenati","year":"1990","unstructured":"Zenati M, Dowling RD, Dummer JS, et al. Influence of the donor lung on development of early infections in lung transplant recipients. J Heart Transplant. 1990;9:502\u20138.","journal-title":"J Heart Transplant"},{"key":"1151_CR30","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of Adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013e111.","journal-title":"Clin Infect Dis"},{"key":"1151_CR31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1060028016673858","volume":"51","author":"JJ Carreno","year":"2017","unstructured":"Carreno JJ, Kenney RM, Divine G, Vazquez JA, Davis SL. Randomized controlled trial to determine the efficacy of early switch from vancomycin to vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT). Ann Pharmacother. 2017;51:185\u201393.","journal-title":"Ann Pharmacother"},{"key":"1151_CR32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CCM.0b013e31822d74a2","volume":"40","author":"P Martinez-Olondris","year":"2012","unstructured":"Martinez-Olondris P, Rigol M, Soy D, et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med. 2012;40:162\u20138.","journal-title":"Crit Care Med"},{"key":"1151_CR33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/1817-1737.172297","volume":"11","author":"S Borekci","year":"2016","unstructured":"Borekci S, Halis AN, Aygun G, Musellim B. Bacterial colonization and associated factors in patients with bronchiectasis. Ann Thorac Med. 2016;11:55\u20139.","journal-title":"Ann Thorac Med"},{"key":"1151_CR34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ejcts\/ezx359","volume":"53","author":"M Zeriouh","year":"2018","unstructured":"Zeriouh M, Sabashnikov A, Patil NP, et al. Use of taurolidine in lung transplantation for cystic fibrosis and impact on bacterial colonization. Eur J Cardiothorac Surg. 2018;53:603\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1151_CR35","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.athoracsur.2018.08.058","volume":"107","author":"A Shah","year":"2019","unstructured":"Shah A, Pasrija C, Boulos F, et al. Decontamination and lung transplantation of a patient with cystic fibrosis with resistant infections. Ann Thorac Surg. 2019;107:e239\u201341.","journal-title":"Ann Thorac Surg"},{"key":"1151_CR36","first-page":"135738","volume":"2012","author":"H Haja Mydin","year":"2012","unstructured":"Haja Mydin H, Corris PA, Nicholson A, et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transp Secur. 2012;2012:135738.","journal-title":"J Transp Secur"},{"key":"1151_CR37","volume":"21","author":"ML Cant\u00f3n-Bulnes","year":"2019","unstructured":"Cant\u00f3n-Bulnes ML, Hurtado Mart\u00ednez \u00c1, L\u00f3pez-Cerero L, Arenzana Seisdedos \u00c1, Merino-Bohorquez V, Garnacho-Montero J. A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy. Transpl Infect Dis. 2019;21:e13034.","journal-title":"Transpl Infect Dis"},{"key":"1151_CR38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2008.02186.x","volume":"8","author":"BD Alexander","year":"2008","unstructured":"Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025\u201330.","journal-title":"Am J Transplant"},{"key":"1151_CR39","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.2007.089458","volume":"63","author":"V Boussaud","year":"2008","unstructured":"Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia Cepacia complex: results from two French Centres. Thorax. 2008;63:732\u20137.","journal-title":"Thorax"},{"key":"1151_CR40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.healun.2010.06.007","volume":"29","author":"A De Soyza","year":"2010","unstructured":"De Soyza A, Meachery G, Hester KLM, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single center experience. J Heart Lung Transplant. 2010;29:1395\u2013404.","journal-title":"J Heart Lung Transplant"},{"key":"1151_CR41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trre.2017.07.001","volume":"32","author":"JM Aguado","year":"2018","unstructured":"Aguado JM, Silva JT, Fern\u00e1ndez-Ruiz M, et al. Management of multidrug resistant gram-negative bacilli infections in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations. Transplant Rev (Orlando). 2018;32:36\u201357.","journal-title":"Transplant Rev (Orlando)"},{"key":"1151_CR42","volume":"28","author":"AK Subramanian","year":"2019","unstructured":"Subramanian AK, Theodoropoulos NM. Infectious diseases Community of Practice of the American Society of Transplantation Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transpl. 2019;28:e13513.","journal-title":"Clin Transpl"},{"key":"1151_CR43","unstructured":"Loi Jard\u00e9. LOI n\u00b0 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine. https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000025441587. Published March 5, 2012. Updated December 31, 2016. Accessed 1 Jan 2017."},{"key":"1151_CR44","unstructured":"D\u00e9lib\u00e9ration n\u00b0 2018\u2013155 du 3 mai 2018 portant homologation de la m\u00e9thodologie de r\u00e9f\u00e9rence relative aux traitements de donn\u00e9es \u00e0 caract\u00e8re personnel mis en \u0153uvre dans le cadre des recherches n'impliquant pas la personne humaine, des \u00e9tudes et \u00e9valuations dans le domaine de la sant\u00e9 (MR-004). https:\/\/www.legifrance.gouv.fr\/affichTexte.do;jsessionid=4941B11FB7C531A046EC7E6199A84A60.tplgfr24s_1?cidTexte=JORFTEXT000037187498&dateTexte=&oldAction=rechJO&categorieLien=id&idJO=JORFCONT000037186583. Published July 13, 2018."},{"key":"1151_CR45","unstructured":"Declaration of Helsinki World Medical Association. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/2013\/. Accessed 24 June 2008."}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-1151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T19:11:56Z","timestamp":1619637116000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1151-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Respondents of the survey gave their consent by completing the survey, choosing which questions to answer. The respondents were informed that the results of the study would be analyzed at the group level; that no individual center data would be able to be identified; and that data would be used for research purposes only. All the clinical cases exposed in the survey were invented by the authors and do not correspond to real cases. No ethical approval was sought for this study which doesn\u2019t involve humans data. The study complies with French law (Loi Jard\u00e9. LOI n\u00b0 2012\u2013300 du 5 mars 2012 and D\u00e9lib\u00e9ration n\u00b0 2018\u2013155 du 3 mai 2018) which requires ethical review only for research involving humans [\n                      \n                      ,\n                      \n                      ] and the World Medical Association and Declaration of Helsinki\u2019s principles for medical research involving human subjects, whose purpose is to protect individuals and ensure respect for human dignity [\n                      \n                      ].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided informed consent for anonymized analysis of their answers and provided their names and the name of their center to be published as collaborators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pr. Marc Leone discloses financial support from MSD (Merck & Co., Inc., Kenilworth, NJ, USA) and Pfizer (Paris, France). Pr. Laurent Papazian reports non-financial support from Dr\u00e4ger SAS France, non-financial support from Maquet SAS France, outside the submitted work. Other authors have no conflict to disclose. Pr. Federica Meloni is a member of the Editorial Board of the BMC Pulmonary Medicine journal as an Associate Editor of the section \u201cInfectious, Rare and Idiopathic Pulmonary Diseases\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}